SPX Technologies, Inc.
SPXCSPX Technologies, Inc. is coiled. The quarters are improving, yet the P/E sits at the 15th percentile of its own 4-year range — the business is moving before the market.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (5 weeks in) while the P/E sits at the 15th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +20.0% year on year, and 141% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
SPX Technologies, Inc. trades at $179, building a base and 5 weeks into that stage. That is −16.4% against its own 200-day average. It sits at 0% of a 52-week range of $179 to $243. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (5 weeks and counting).
Today the stock is building a base — week 5 of stage 1. At $179 it trades −16.4% versus its 200-day average and sits at 0% of its 52-week range ($179–$243).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +1,083% while the S&P 500 moved +255% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (5 weeks and counting; last ahead the week of 2026-08-14) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
SPX Technologies, Inc. trades at 32.2× P/E, near the bottom of its own range — cheaper only 15% of the time. Its long-run median P/E is 45.2×, measured across 4.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 32.2× is near the bottom of its own range — cheaper only 15% of the time, against a long-run median of 45.2× measured over 4.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +18.1% against a −5.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +31.2%/yr price move, ~+61.7%/yr came from earnings growth and ~−30.5 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
SPX Technologies, Inc. reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 12.5% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +14.6% | +15.8% | — | — |
| Profit | +25.0% | +132.1% | — | — |
| EPS | +18.1% | — | — | — |
| Stock price | −5.0% | +31.2% | +26.8% | +24.8% |
4-Factor Sector Score
46.4/100 — rank 13 of 29 in Building Products & Equipment · 58% evidence confidence
SPX Technologies, Inc. scores 46.4 out of 100 against the 29 companies it is compared with in Building Products & Equipment, ranking 13. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 20.4 + 13.5 + 9.6 + 2.9 = 46.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
SPX Technologies, Inc. reported $0.6 B of revenue in the Mar 26 quarter, +18.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 16.8% a year. The last full year, FY25, came in at $2.3 B. The last four reported quarters add to $2.4 B.
FY25 revenue came in at $2.3 B (+14.6% on the year), capping 4 years at 16.8% compound. The latest quarter (Mar 26) printed $0.6 B, +18.8% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +18.1% growth against the decade's 16.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +18.1% over the last 4 quarters against +13.9%/yr over the last 8 — accelerating; TTM profit +19.0% vs +25.0%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
SPX Technologies, Inc.'s operating margin is 15.8% in the Mar 26 quarter, +1.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 3.4% to 15.7%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 15.8%, +1.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 3.4%–15.7%.
Why the margin moved: operating margin went +1.2 pp year on year while gross margin went −1.3 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
SPX Technologies, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +20.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY25 profit was $0.3 B. The 4-year compound rate is 42.9%. That is 10.5% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.
Mar 26 profit was $0.1 B, +20.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY25 printed $0.3 B (+25.0%), and the 4-year compound rate is 42.9%.
Why profit moved: revenue contributed +18.8% and the margin +1.2 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +18.3% vs revenue +18.1%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 141% of SPX Technologies, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.3 B of operating cash against $0.3 B of profit. After $0.1 B of capital spending, $0.2 B was left as free cash.
FY25: operating cash of $0.3 B against reported profit of $0.3 B, leaving free cash of $0.2 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 141% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
SPX Technologies, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
SPX Technologies, Inc. earns a ROE of 11% in FY25. That is up from a trough of 2% in FY22. Return on invested capital clears the cost of that capital by +0.1 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.0% net margin on 0.63× asset turns.
FY25 ROE is 11%, recovered from a FY22 trough of 2% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 11.0% net margin × 0.63× asset turns × 1.61× balance-sheet leverage ≈ 11.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.9% − 10.8% = a +0.1 pp spread. The 10.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend
SPX Technologies, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
SPX Technologies, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
SPX Technologies, Inc. carries total debt of $0.6 B against shareholder equity of $2.4 B as of Jun 26, a debt-to-equity of 0.26 — effectively unlevered. On the annual view that ratio went from 0.23 in FY21 to 0.22 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of $0.6 B against shareholder equity of $2.4 B — a debt-to-equity of 0.26. On the annual view, debt-to-equity went from 0.23 (FY21) to 0.22 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.1% of SPX Technologies, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.1% of the float is sold short, and at typical trading volumes it would take about 3.6 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
SPX Technologies, Inc.: the Z-score reads 5.15. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 5.15 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 5.15.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Johnson Controls International plcJCI | 67.5/100Favorable setup85% evidence | ASLEEP | 24.0/35 Revenue 6.8% · PAT 9.9% · OPM change 2 pp 95% evidence | 12.3/25 ROCE 3.4% · OPM 14.9% 76% evidence | 14.7/20 P/E 25.4× · PEG 0.48 65% evidence | 16.5/20 RS sector 14% · RS bench 0.3% · 1Y 29.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 12.3 + 14.7 + 16.5 = 67.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Masco CorporationMAS | 63.4/100Thin evidence · provisional58% evidence | ASLEEP | 21.4/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 17.8/25 ROCE 12.6% · OPM 16.5% 76% evidence | 11.0/20 P/E 18.7× · PEG — 15% evidence | 13.2/20 RS sector 5.6% · RS bench -7.4% · 1Y -5.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 17.8 + 11 + 13.2 = 63.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Trex Company, Inc.TREX | 59.0/100Mixed-positive evidence81% evidence | ASLEEP | 17.2/35 Revenue 5.3% · PAT -3.5% · OPM change 0.3 pp 83% evidence | 16.5/25 ROCE 7.6% · OPM 24.3% 76% evidence | 9.2/20 P/E 20.3× · PEG 1.98 65% evidence | 16.1/20 RS sector 9.9% · RS bench -3.9% · 1Y -18.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 16.5 + 9.2 + 16.1 = 59 · Decision use: Price leads the evidence: RS versus the benchmark is -3.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4Griffon CorporationGFF | 58.3/100Mixed-positive evidence81% evidence | FADING | 13.6/35 Revenue -0.8% · PAT -71.7% · OPM change -0.6 pp 83% evidence | 13.6/25 ROCE 4.8% · OPM 20.7% 76% evidence | 12.5/20 P/E 559.1× · PEG 0.54 65% evidence | 18.6/20 RS sector 18.2% · RS bench 3.9% · 1Y 22.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 13.6 + 12.5 + 18.6 = 58.3 · Decision use: Price leads the evidence: RS versus the benchmark is 3.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5Apogee Enterprises, Inc.APOG | 57.9/100Mixed-positive evidence71% evidence | ASLEEP | 20.8/35 Revenue 1.8% · PAT 37.3% · OPM change 3.5 pp 71% evidence | 9.2/25 ROCE 2.1% · OPM 5.5% 76% evidence | 16.0/20 P/E 12× · PEG 0.33 65% evidence | 11.9/20 RS sector 5% · RS bench -8.1% · 1Y -14%6 of 12 weeks ahead 70% evidence |
| Exact sum: 20.8 + 9.2 + 16 + 11.9 = 57.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Carlisle Companies IncorporatedCSL | 54.3/100Thin evidence · provisional58% evidence | ASLEEP | 19.9/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 15.6/25 ROCE 6.9% · OPM 17.1% 76% evidence | 10.6/20 P/E 20.8× · PEG — 15% evidence | 8.2/20 RS sector -2.2% · RS bench -14.3% · 1Y -6.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 15.6 + 10.6 + 8.2 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Armstrong World Industries, Inc.AWI | 54.0/100Thin evidence · provisional58% evidence | ASLEEP | 17.6/35 Revenue — · PAT — · OPM change -2.7 pp 45% evidence | 16.7/25 ROCE 8% · OPM 23% 76% evidence | 10.5/20 P/E 22× · PEG — 15% evidence | 9.2/20 RS sector -5% · RS bench -16.9% · 1Y -19.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 16.7 + 10.5 + 9.2 = 54 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Arlo Technologies, Inc.ARLO | 52.1/100Thin evidence · provisional58% evidence | TURNING | 23.4/35 Revenue 10.7% · PAT — · OPM change 6.2 pp 62% evidence | 9.3/25 ROCE 5% · OPM 5% 76% evidence | 9.5/20 P/E 47.8× · PEG — 15% evidence | 9.9/20 RS sector 1.3% · RS bench -11.4% · 1Y -25.8%1 of 12 weeks ahead 70% evidence |
| Exact sum: 23.4 + 9.3 + 9.5 + 9.9 = 52.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9NPK International Inc.NPKI | 50.1/100Thin evidence · provisional52% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence | 12.4/25 ROCE 4.3% · OPM 19.2% 76% evidence | 9.9/20 P/E 31.8× · PEG — 15% evidence | 9.8/20 RS sector 1.3% · RS bench -11% · 1Y 18.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18 + 12.4 + 9.9 + 9.8 = 50.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Trane Technologies plcTT | 49.9/100Mixed-negative evidence85% evidence | ASLEEP | 18.8/35 Revenue 7% · PAT 4.4% · OPM change -1 pp 95% evidence | 16.8/25 ROCE 8.2% · OPM 19.3% 76% evidence | 5.0/20 P/E 37.2× · PEG 4.26 65% evidence | 9.3/20 RS sector 2.2% · RS bench -10.2% · 1Y 3.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 16.8 + 5 + 9.3 = 49.9 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 11Perma-Pipe International Holdings, Inc.PPIH | 49.2/100Mixed-negative evidence79% evidence | TURNING | 15.2/35 Revenue 24.4% · PAT 5.9% · OPM change -7.7 pp 95% evidence | 10.6/25 ROCE 3.4% · OPM 9.2% 76% evidence | 9.0/20 P/E 19.3× · PEG 2 65% evidence | 14.4/20 RS sector 11.7% · RS bench -1.9% · 1Y 27%1 of 12 weeks ahead 70% evidence |
| Exact sum: 15.2 + 10.6 + 9 + 14.4 = 49.2 · Decision use: Price leads the evidence: RS versus the benchmark is -1.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 12Aspen Aerogels, Inc.ASPN | 46.8/100Thin evidence · provisional58% evidence | ASLEEP | 20.0/35 Revenue -47.4% · PAT — · OPM change 325.2 pp 62% evidence | 3.0/25 ROCE -5.2% · OPM -55% 76% evidence | 8.9/20 P/E 69.9× · PEG — 15% evidence | 14.9/20 RS sector 13.3% · RS bench -1.3% · 1Y -27.9%5 of 12 weeks ahead 70% evidence |
| Exact sum: 20 + 3 + 8.9 + 14.9 = 46.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13SPX Technologies, Inc.this pageSPXC | 46.4/100Thin evidence · provisional58% evidence | ASLEEP | 20.4/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence | 13.5/25 ROCE 3.7% · OPM 15.5% 76% evidence | 9.6/20 P/E 41.6× · PEG — 15% evidence | 2.9/20 RS sector -9.5% · RS bench -20.6% · 1Y -5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 13.5 + 9.6 + 2.9 = 46.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Lennox International Inc.LII | 44.8/100Thin evidence · provisional58% evidence | ASLEEP | 15.1/35 Revenue — · PAT — · OPM change -1.3 pp 45% evidence | 17.7/25 ROCE 13.3% · OPM 14.4% 76% evidence | 10.2/20 P/E 25.9× · PEG — 15% evidence | 1.8/20 RS sector -22.1% · RS bench -31.9% · 1Y -33.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 17.7 + 10.2 + 1.8 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Latham Group, Inc.SWIM | 44.4/100Mixed-negative evidence64% evidence | BREAKING OUT | 16.1/35 Revenue 8.7% · PAT — · OPM change -1.2 pp 62% evidence | 4.3/25 ROCE -0.9% · OPM -5.6% 76% evidence | 8.8/20 P/E 75.6× · PEG — 15% evidence | 15.2/20 RS sector 5.2% · RS bench -8% · 1Y -18.1%7 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 4.3 + 8.8 + 15.2 = 44.4 · Decision use: Price leads the evidence: RS versus the benchmark is -8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Quanex Building Products CorporationNX | 44.0/100Mixed-negative evidence69% evidence | BREAKING OUT | 10.4/35 Revenue 14.3% · PAT -8166.7% · OPM change -5 pp 95% evidence | 6.5/25 ROCE 1% · OPM 4% 76% evidence | 10.1/20 P/E 27.9× · PEG — 15% evidence | 17.0/20 RS sector 25.8% · RS bench 10.6% · 1Y 51.2%5 of 12 weeks ahead 70% evidence |
| Exact sum: 10.4 + 6.5 + 10.1 + 17 = 44 · Decision use: Price leads the evidence: RS versus the benchmark is 10.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 17Carrier Global CorporationCARR | 42.4/100Mixed-negative evidence85% evidence | ASLEEP | 13.5/35 Revenue -1.6% · PAT -22.8% · OPM change -1.4 pp 95% evidence | 11.4/25 ROCE 2.6% · OPM 12.1% 76% evidence | 13.0/20 P/E 50.9× · PEG 0.66 65% evidence | 4.5/20 RS sector -4.5% · RS bench -16.2% · 1Y -10.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 11.4 + 13 + 4.5 = 42.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Fortune Brands Innovations, Inc.FBIN | 42.2/100Mixed-negative evidence81% evidence | ASLEEP | 11.8/35 Revenue -2% · PAT -36.5% · OPM change -3.4 pp 83% evidence | 9.7/25 ROCE 1.1% · OPM 6% 76% evidence | 13.4/20 P/E 17× · PEG 0.93 65% evidence | 7.3/20 RS sector -10.9% · RS bench -22.2% · 1Y -29.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 9.7 + 13.4 + 7.3 = 42.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19AirJoule Technologies CorporationAIRJ | 42.2/100Thin evidence · provisional52% evidence | ASLEEP | 11.9/35 Revenue — · PAT -249% · OPM change — 57% evidence | 5.7/25 ROCE -1.1% · OPM — 61% evidence | 11.4/20 P/E 8.7× · PEG — 15% evidence | 13.2/20 RS sector 8.3% · RS bench -5.2% · 1Y -13.9%8 of 12 weeks ahead 70% evidence |
| Exact sum: 11.9 + 5.7 + 11.4 + 13.2 = 42.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20AAON, Inc.AAON | 41.9/100Mixed-negative evidence81% evidence | ASLEEP | 22.1/35 Revenue 28.2% · PAT -25.8% · OPM change 0.6 pp 83% evidence | 13.3/25 ROCE 4.5% · OPM 11.5% 76% evidence | 4.8/20 P/E 57.9× · PEG 4.21 65% evidence | 1.7/20 RS sector -17.5% · RS bench -27.8% · 1Y -17.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 13.3 + 4.8 + 1.7 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Owens CorningOC | 41.3/100Mixed-negative evidence64% evidence | ASLEEP | 9.0/35 Revenue -5.1% · PAT -308.2% · OPM change -10.8 pp 62% evidence | 7.0/25 ROCE 1.1% · OPM 5.3% 76% evidence | 9.8/20 P/E 35.7× · PEG — 15% evidence | 15.5/20 RS sector 8.1% · RS bench -5.2% · 1Y -13%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 7 + 9.8 + 15.5 = 41.3 · Decision use: Price leads the evidence: RS versus the benchmark is -5.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Gibraltar Industries, Inc.ROCK | 38.9/100Mixed-negative evidence75% evidence | BREAKING OUT | 11.9/35 Revenue 21.1% · PAT -54.1% · OPM change -12.9 pp 83% evidence | 6.8/25 ROCE -0.3% · OPM -1.3% 76% evidence | 11.3/20 P/E 314× · PEG 0.92 65% evidence | 8.9/20 RS sector -0.2% · RS bench -13.1% · 1Y -27.5%8 of 12 weeks ahead 70% evidence |
| Exact sum: 11.9 + 6.8 + 11.3 + 8.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Janus International Group, Inc.JBI | 38.4/100Thin evidence · provisional58% evidence | ASLEEP | 13.3/35 Revenue — · PAT — · OPM change -9.9 pp 45% evidence | 8.2/25 ROCE 1.1% · OPM 5.9% 76% evidence | 11.2/20 P/E 15.9× · PEG — 15% evidence | 5.7/20 RS sector -25% · RS bench -35% · 1Y -57.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 8.2 + 11.2 + 5.7 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24JELD-WEN Holding, Inc.JELD | 35.9/100Thin evidence · provisional58% evidence | 20.1/35 Revenue -12.1% · PAT — · OPM change 16.2 pp 62% evidence | 3.5/25 ROCE -3.3% · OPM -7.6% 76% evidence | 9.3/20 P/E 57.4× · PEG — 15% evidence | 3.0/20 RS sector -58.7% · RS bench -62.8% · 1Y -77.3%1 of 4 weeks ahead to 2026-07-24 70% evidence | |
| Exact sum: 20.1 + 3.5 + 9.3 + 3 = 35.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Limbach Holdings, Inc.LMB | 35.5/100Mixed-negative evidence81% evidence | BASING | 14.8/35 Revenue 22.5% · PAT 0% · OPM change -5.1 pp 83% evidence | 7.2/25 ROCE 0.5% · OPM 0.8% 76% evidence | 12.0/20 P/E 28.4× · PEG 0.94 65% evidence | 1.5/20 RS sector -27.2% · RS bench -36.6% · 1Y -50.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 7.2 + 12 + 1.5 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Louisiana-Pacific CorporationLPX | 33.5/100Adverse evidence81% evidence | ASLEEP | 5.7/35 Revenue -13% · PAT -79% · OPM change -10.7 pp 83% evidence | 8.8/25 ROCE 1.5% · OPM 5.9% 76% evidence | 14.0/20 P/E 62.2× · PEG 0.28 65% evidence | 5.0/20 RS sector -11.8% · RS bench -23% · 1Y -26%0 of 12 weeks ahead 100% evidence |
| Exact sum: 5.7 + 8.8 + 14 + 5 = 33.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 27Builders FirstSource, Inc.BLDR | 33.5/100Thin evidence · provisional58% evidence | ASLEEP | 13.9/35 Revenue — · PAT — · OPM change -4.5 pp 45% evidence | 8.4/25 ROCE 1.3% · OPM 0.5% 76% evidence | 8.7/20 P/E 98.3× · PEG — 15% evidence | 2.5/20 RS sector -31.8% · RS bench -40.8% · 1Y -52%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 8.4 + 8.7 + 2.5 = 33.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Advanced Drainage Systems, Inc.WMS | 32.3/100Adverse evidence81% evidence | ASLEEP | 11.8/35 Revenue 5% · PAT -5.4% · OPM change -11.1 pp 83% evidence | 10.8/25 ROCE 1.5% · OPM 7.9% 76% evidence | 5.4/20 P/E 25.2× · PEG 4.38 65% evidence | 4.3/20 RS sector -7.3% · RS bench -18.8% · 1Y -11.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 10.8 + 5.4 + 4.3 = 32.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Madison Air Solutions CorporationMAIR | 54.7/100Thin evidence · provisional27% evidence | ASLEEP | 18.2/35 Revenue — · PAT — · OPM change -1.4 pp 13% evidence | 15.0/25 ROCE 5.1% · OPM 16.4% 76% evidence | 11.5/20 P/E 0× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 18.2 + 15 + 11.5 + 10 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is SPX Technologies, Inc.'s stock price today?
SPX Technologies, Inc. trades at $179, −5.0% over the past year. The company is valued at $9.0 B. The stock sits at the very bottom of its 52-week range ($179–$243), −16.4% versus its 200-day average. On the tape, the price is building a base, 5 weeks in. — as of 17 September 2026.
What were SPX Technologies, Inc.'s latest quarterly results?
SPX Technologies, Inc. reported revenue of $0.6 B and net profit of $0.1 B for the Mar 26 quarter. Revenue rose 18.8% and profit rose 20.0% year on year. Earnings per share were $1.19. The operating margin was 15.8%, 1.2 pp higher than a year earlier. — as of 17 September 2026.
What is SPX Technologies, Inc.'s revenue?
SPX Technologies, Inc. reported revenue of $0.6 B in the Mar 26 quarter, +18.8% year on year. For the full FY25 fiscal year, revenue was $2.3 B (+14.6%). Over the last 4 years revenue compounded at 16.8% a year. — as of 17 September 2026.
What is SPX Technologies, Inc.'s profit?
SPX Technologies, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +20.0% year on year — the 3rd straight quarter of growth. Full-year FY25 profit was $0.3 B. The operating margin ran 15.8% in the latest quarter. — as of 17 September 2026.
What is SPX Technologies, Inc.'s market cap?
SPX Technologies, Inc.'s market capitalisation is $9.0 B at a stock price of $179. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is SPX Technologies, Inc.'s P/E ratio?
SPX Technologies, Inc. trades at a P/E of 32.2×, at the 15th percentile of its own 4-year range, against a long-run median of 45.2×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does SPX Technologies, Inc. pay a dividend?
No — SPX Technologies, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is SPX Technologies, Inc. overvalued?
On its own history, SPX Technologies, Inc. looks cheap: its P/E of 32.2× has been cheaper only 15% of the time in 4 years (long-run median 45.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is SPX Technologies, Inc. growing?
Yes — SPX Technologies, Inc. is growing: latest-quarter revenue +18.8% year on year, profit +20.0%, and the margin +1.2 pp at 15.8%. The 4-year compound rates are 16.8% (revenue) and 42.9% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is SPX Technologies, Inc. performing?
SPX Technologies, Inc. is building a base, 5 weeks in. Its latest quarter's revenue rose 18.8% and profit rose 20.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is SPX Technologies, Inc. in?
Mixed — the growth curves are steadily positive, but ROCE at 12.5% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +18.1% latest, profit growth +19.0% latest, eps growth +18.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is SPX Technologies, Inc. in an uptrend?
No — the price is building a base (week 5 of stage 1), trading −16.4% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is SPX Technologies, Inc. beating the market?
Not lately — on a trailing-13-week view SPX Technologies, Inc. is currently behind the S&P 500 (5 weeks and counting; last ahead the week of 2026-08-14), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +1,083% against the S&P 500's +255% — ahead of the index over the full window. — as of 17 September 2026.
Will SPX Technologies, Inc.'s stock price go up?
This page publishes no price forecast for SPX Technologies, Inc. What it measures instead: the stock price is $179, the price is building a base 5 weeks in. Its P/E of 32.2× sits at the 15th percentile of its own 4-year range. — as of 17 September 2026.
Is the market betting against SPX Technologies, Inc.?
Somewhat — short interest is 3.1% of SPX Technologies, Inc.'s tradable float, about 3.6 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does SPX Technologies, Inc. have too much debt?
No — SPX Technologies, Inc.'s debt-to-equity is 0.26. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.
What is SPX Technologies, Inc.'s capex?
SPX Technologies, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 17 September 2026.
What is SPX Technologies, Inc.'s cash flow?
SPX Technologies, Inc. generated $0.3 B of operating cash flow in FY25 and $0.2 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.3 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is SPX Technologies, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 141% of SPX Technologies, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.3 B against reported profit of $0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is SPX Technologies, Inc.?
On the balance sheet, the Z-score reads 5.15 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is SPX Technologies, Inc. in its business cycle?
SPX Technologies, Inc.'s FY25 operating margin was 15.4%, against a 5-year band of 3.4%–15.7%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 15.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the SPX Technologies, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is SPX Technologies, Inc. a stock worth studying right now?
This is not investment advice. The machine read: SPX Technologies, Inc. is coiled. The quarters are improving, yet the P/E sits at the 15th percentile of its own 4-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!